Stanford phd candidate Calvin schmidt posts about investing opportunities in synthetic biology. Available for consulting on potential investments in this area.

Calvin Schmidt Synthetic Biology Index: February Update

Performance overview
Value at beginning of month: $97,329.36
Value at end of month: $98,120.95
Month over month change: +0.81%
Total CAGR: -15.16%

Related indices, monthly change
NASDAQ: +3.35%
IVV (iShares Core S&P 500): +3.25%
IBB (iShares NASDAQ Biotechnology Index): +6.70%
MXI (iShares Global Materials): -1.64%
VEGI (iShares MSCI Global Agriculture Producers): -0.52%

Individual performances

CSSBI - Price Tracker (2)-1.png

The three giants of the index, Novozymes, Intrexon, and Genscript, all exhibited small-to-modest gains, carrying the index to a positive quarter. Most of the smaller companies lost value, led by a group of chemicals companies that were down by double digits for the second month in a row (Gevo, Amyris, and Bioamber).  Gevo performed the worst, due to an announcement that they are issuing $12M in new shares while holding a market cap of about $12M, which cut the price of the stock in half.

Changes made to index
Removed the AquaBounty Technologies stock ABTU.L and added the company’s more commonly traded stock, AQB.

Allocation as of January 28, 2017

Calvin Schmidt Synthetic Biology Index: March Update

CSSBI January Update